REVADIM, Israel, May 24, 2019 /CNW/ – Breath of Life International Ltd. (“BOL Pharma”) today announced that it has filed a preliminary prospectus with the securities regulatory authorities in each of the provinces and territories of Canada for a proposed initial public offering of ordinary shares (the “Offering”). Copies of the preliminary prospectus are available on SEDAR at

The Offering is being co-led by BMO Nesbitt Burns Inc., Cowen & Company LLC and Scotia Capital Inc. as joint bookrunners.

No securities regulatory authority has either approved or disapproved of the contents of this news release. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities of BOL Pharma in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful. The preliminary prospectus contains important information relating to the ordinary shares and is still subject to completion or amendment. There will not be any sale or any acceptance of an offer to buy the ordinary shares until a receipt for the final prospectus has been issued. This news release does not provide full disclosure of all material facts relating to the securities offered. Investors should read the preliminary prospectus, final prospectus and any amendment, for disclosure of those facts, especially risk factors relating to the securities offered, before making an investment decision. The ordinary shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws. Accordingly, the ordinary shares may not be offered or sold within the United States except pursuant to exemptions from the registration requirements of the U.S. Securities Act and applicable state securities laws.

About BOL Pharma

BOL Pharma is a leading, vertically-integrated producer of medical cannabis and cannabis products in Israel, supplying patients, pharmacies and other participants in the medical cannabis and pharmaceutical industries, and targeting export markets in the EU, as well as Canada and Australia. BOL Pharma plans to become a global leader in producing medical cannabis and innovative cannabis products, including new pharmaceutical drugs intended to address unmet medical needs of patients in therapeutic areas including central nervous system disorders, pain and palliative care management, and inflammation and autoimmune disorders. BOL Pharma has a number of products under development and is collaborating with leading medical centers and research facilities across Israel to support a clinical program spanning more than 30 indications. BOL Pharma currently has 377,000 square feet of operational greenhouses and highly scalable cultivation, as well as 65,000 square feet of IMC-GMP accredited manufacturing operations headquartered in Revadim, Israel, and is currently expanding its operations to Portugal.

SOURCE Breath of Life International Ltd.

For further information: Hugo Goldman, Chief Financial Officer, Tel: +1 718-838-1159, or Ross Marshall, LodeRock Advisors Inc., Tel: +1 (416) 526-1563,